Usage Test on a New Cosmetic Product: Mouthwash

NCT ID: NCT06808711

Last Updated: 2025-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-02

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to learn if a new mouthwash can help soothing oral mucosa in adult patients with sensitive gums. The main questions it aims to answer are:

* Does the investigated mouthwash soothe red gum?
* Has the mouthwash antibacterial activities? Researchers will compare with a marketed mouthwash to see if the observed effect is due to the formula or to the general rinsing effect of any mouthwash.

Participants will be asked to use the investigated mouthwash or the comparative mouthwash twice a day for 21 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Severity of gingival inflammation is evaluated using the Loë \& Silness scale, which includes 4 scores (0=no inflammation, 3=Significant inflammation, redness, accentuated hypertrophy with spontaneous hemorrhagic tendency and ulceration) by the dentist, on Day 0 and on Day 7.

Presence of dental plaque is evaluated using the Loë \& Silness scale, which includes 4 scores (0=no dental plaque, 3=Abundant plaque along the gingival margin; the spaces between the teeth are filled with plaque) by the dentist, on Day 0 and on Day 7.

Changes in the gingival microbiota is evaluated through the analysis of bacteria on D0 and D7 by swab sampling on the occlusal and buccal surfaces at the gum line.

Tolerance (adverse effects) will also be studied by recording any adverse effect.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sensitive Gum Gum Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Buccocéan

Mouthwash, twice a day

Group Type EXPERIMENTAL

Buccocéan mouthwash

Intervention Type OTHER

Normal conditions of use

Marketed mouthwash

Mouthwash, twice a day

Group Type ACTIVE_COMPARATOR

Marketed mouthwash

Intervention Type OTHER

Normal conditions of use

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Buccocéan mouthwash

Normal conditions of use

Intervention Type OTHER

Marketed mouthwash

Normal conditions of use

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Person (man, woman) aged 18 or over,
* Person with a gingival index ≥ 2 (according to Loë \& Silness) on at least 10% of teeth (i.e. 3 teeth) at the inclusion visit
* Person capable of following the instructions for using the product,
* Person agreeing to come for a dental consultation 7 days (+/- 1 day) after the inclusion visit,
* Volunteer informed and having signed their informed consent form,
* Volunteer person affiliated to a social security scheme (Art L1121-11 of the CSP).

Exclusion Criteria

* Person who has regularly used mouthwash in the last month,
* Person suffering from periodontitis
* Person having a scaling treatment planned in the session, or having had a scaling treatment in the 6 months preceding the inclusion visit,
* Person having had antibiotic or antifungal treatment in the 3 months preceding the visit,
* Person taking anti-coagulant or anti-aggregant or immunosuppressive or anti-cancer treatment (chemotherapy or radiotherapy of the head and neck)
* Person at risk of infective endocarditis,
* Person with a known sensitivity or allergy to one of the components of mouthwashes, including components derived from essential oils (Eucalyptol, thymol, menthol, limonene).
* Volunteer participating in intervention research.
* Vulnerable people referred to in articles L. 1121-5 to 8 and L. 1122-1-2 of the Public Health Code (institutionalized volunteers, deprived of their liberty or placed under legal protection (guardianship or curatorship).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

YSLab

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dentistry center

Rennes, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BUCCOCEAN

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.